Cosmetic compositions including human serum albumin obtained out of transgenic animals, not out of men |
|
IPC classes for russian patent Cosmetic compositions including human serum albumin obtained out of transgenic animals, not out of men (RU 2247554):
  
 Cosmetic compositions / 2247553
The present innovation deals with either antiperspirant or deodorizing composition either in solid or soften-solid form including either antiperspirant or deodorizing active substance and a continuous phase that contains a liquid water-unmixed carrier and, also, it contains a structurizing agent being either completely or partially esterifying cellobiose of formula (I), in which every Z independently represents either hydrogen or acyl group of formula (II)
Cream for facial skin / 2246933
The suggested facial cream contains acetylated lanolin, olive oil, cacao oil, ethanol, glycerol, honey, germaben, triethanolamine, flavoring, bee wax, zinc stearate, stearin, methylcellulose, albumin fraction of caprine milk whey, fucoidan hydrolyzate, distilled water. Components should be taken at certain quantitative content. Cream favors wounds healing, improves metabolic processes in skin cells and prevents skin aging and its dryness and desquamation, as well.
 Wet napkins favorably treating skin / 2246319
Device has emulsion composition of oil-in-water type containing natural fat or oil, sterol or sterol derivatives, moisture trap, emulsifying surfactant and water.
External agent for prophylaxis of skin infectious disease and method for prophylaxis / 2246292
Invention proposes a cosmetic agent for prophylaxis of skin infectious diseases that comprises an active substance and a conducting agent - multilamellar liposomes additionally. As an active substance dioxydin is used in the amount 0.00001-0.02 wt.-% to the external agent mass. Method for prophylaxis of skin infectious diseases involves using a cosmetic agent in the form of spoon or shampoo, or gel, or cream in the dose depending on selection of the composition and properties of cosmetic agent. Applying the agent results to reducing injurious effect on skin normal microflora, reducing danger from penetration of preparation in blood and providing high protection of skin against all species of infection. Invention can be used for prophylaxis of skin diseases in humans.
Cosmetic gel for facial skin / 2245707
The suggested cosmetic gel for facial skin contains a gel-forming component as acrylic acid copolymer - carbopol, a pH regulator as triethanolamine, a conservant, a flavoring, a biologically active additive and water, moreover, as a biologically active additive one should apply either fullerens or schungite water, oil of wheat sprouts, tocopherol acetate (vitamin E), vitamin A, vitamin F: components should be taken at a certain quantitative ratio. The suggested cosmetic gel for facial skin is of antiphlogistic, moisturizing and antioxidant action at simultaneous nourishing patient's skin with oxygen. The gel tones, softens and nourishes facial skin, improves cutaneous respiration. It is nontoxic and causes no allergic reactions.
Product designed as cosmetic wipes / 2245706
The present method deals with a product designed as disposable cosmetic wipes that contain soft water-insoluble substrate such as tissue impregnated with either alpha- or beta-hydroxycarbonic acid in cosmetically acceptable carrier-foundation. Impregnating cosmetic compositions will have pH of not above 6.8 in water. Silicone microemulsion is available to minimize stickiness being the result of applying hydroxycarbonic acid upon skin with the above-suggested wipes. In the presence of surface-active substances that contain groups of fatty acid, silicone microemulsion prevents the appearance of unpleasant odors which could be produced by surface-active substance in the course of hydrolysis at low pH.
 Method for production of oil enriched in fatty hydroxyoctadecadienic acids (hode) or esters thereof from oil mixture containing linoleic acid or esters thereof / 2245358
Target oil, enriched in HODE, or esters thereof is obtained by controlled oxidation of linoleic acid and/or linolenic acid or esters thereof in presence of oxidation catalyst. Oxidation is stopped when total HODE or ester content is more than 5 %, and/or content of isomeric 9-hydroxy-10,12-octadecadienic acid (9-HODE) or esters thereof is more than 1,5 %; and hydroperoxides formed in oxidation process are reduced with reducing agent in presence of antioxidant. Invention is also relates to oil enriched in 9-HODE or esters or salts thereof having an lipolytic action; to drug or food additive for obesity treatment; cosmetic for local treatment of cellulite. Compound for controlling of adipocyte lipolytic activity and hydrolysis of triglycerides accumulated in adipocytes is also disclosed.
Method for correcting cosmetic skin defects / 2245131
One should carry out multiple desquamation by applying a preparation containing alpha-hydroacids, moreover, before desquamation one should purify skin against contamination and sebum with a preparation containing alpha-hydroacids and urea, moisten with a preparation at pH being 4.5-6.5 and then conduct desquamation with a preparation at pH being 1.6-2.2 by applying glycolic acid at 30-70% concentration as alpha-hydroacid, then one should activate reparative skin properties with a preparation containing isoflavones and soybean lecithin and restore functional properties of epidermal lipid barrier and protect skin against negative impact with a phospholipid-containing preparation upon lamellar basis. Moreover, moistening should be carried out with a preparation containing ascorbic acid or its derivatives, hydrolyzates of hyaluronic acid and collagen and polysiloxanes, and desquamation should be carried out with a preparation containing, additionally, hydrolyzates of mucoplysaccharides and proteins. Moreover, as alpha-hydroacids one should apply the mixture of glycolic and lactic acids, activation of reparative capacity of skin cells should be performed with a preparation containing the complex of vitamins A, E, F and C, and restoration of functional properties of epidermal lipid barrier and skin protection against negative impacts - with compositions upon lamellar basis with the complex of vitamins and hydrophobic film-forming substances. Moreover, to create lamellar basis it is necessary to apply the mixture of soybean lecithin, jojoba oil and unsaturated fatty acids.
Method for activating restorative skin processes / 2245130
One should carry out purification, desquamation and regeneration of skin, moreover, problematic skin should be desquamated before regeneration, and regeneration should be conducted by stages, moreover, at the first stage skin should be moistened, at the second stage it should be nourished and at the third stage one should restore its barrier function and protect the skin against environmental factors, and nutrition and restoration of skin epidermal barrier should be carried out with a preparation based upon soybean isoflavones, phytic acid, extracts of Iceland moss and bioactive preparations of maritime genesis. As for moistening it should be carried out with a preparation based upon vitamin C, hydrolyzates of collagen, elastin and hyaluronic acid; before desquamation one should additionally moisten the skin; nutrition and restoration of skin epidermal barrier should be fulfilled with a preparation based upon lamellar composition containing soybean isoflavones, phytic acid, extract of Iceland moss and bioactive preparations of maritime genesis. Moreover, additionally after moistening one should carry out antiphlogistic treatment of skin by applying gelatinous preparations containing plant extracts, allantoin, d-pantenol and amino acids, and as a preparation to restore skin barrier function and its protection against environmental unfavorable factors one should apply composition containing essential oils, plant extracts, vitamins K, A, C, E, F and microelements, as well.
Cosmetic gel for taking care of facial skin / 2244540
The suggested cosmetic gel contains a gel-forming component, a moisturizing component either glycerol or propylene glycol, a conservant, flavoring, biologically active additive and water, moreover, as biologically active additive - fullerens or schungite water and yarrow extract and, additionally, it contains a conditioner - dimethycone, a softening agent - trilon B, a moisturizing component - hyaluronic acid. Components should be taken at a certain quantitative ratio. Gel is of antiphlogistic, moisturizing and antioxidant action at simultaneous saturation of skin with oxygen. The suggested gel tones, softens and nourishes facial skin, improves skin respiration, it is toxic and causes no allergic reactions.
 Cosmetic compositions including human serum albumin obtained out of transgenic animals, not out of men / 2247554
Human serum albumin (HAS) should be obtained out of transgenic animals, not out of men, to be mixed with corresponding carrier and/or adjuvant. HAS should be obtained out of cattle, sheep, swine, horse, rodents or goat. HAS should be obtained either out of milk or blood of transgenic animals, not out of men. HAS should be obtained out of an egg of transgenic poultry. Cosmetic composition should be obtained due to similar technique. Cosmetic composition is either lotion, cream, gel or oil to be applied in case of cosmetic treating wrinkles, scars and burn wounds. The present innovation enables to cheapen the product at keeping its high activity.
 Somatostatin agonists / 2263677
Invention proposes agonists of somatostatin of the formula (I): X-A1-cyclo-(D-Cys-A3-A4-Lys-A6-A7)-A8-Y or its pharmaceutically acceptable salt wherein X represents hydrogen atom (H); A1 represents L-Cpa, L-Phe, L-Trp or L-Nal; A3 represents L-3-Pal or L-4-Pal; A4 represents D-Trp; A6 represents -NH-(CHR1)n-CO- wherein n = 2, 3 or 4; A7 represents L- or D-Cys; A8 represents D- or L-isomer of amino acid taken among the group consisting of Nal, Phe, Cpa and Trp; Y represents NH2; R1 represents hydrogen atom (H), and Cys in A3 is bound by disulfide bong in A wherein this disulfide bond is formed by thiol groups of each Cys residue.
Method for treating hepatic failure / 2269363
The present innovation deals with the ways of extracorporal detoxication and treatment of hepatic failure. The method should be implemented due to introducing albumin-containing solution through a catheter into abdominal cavity at concentration of 30-40 g/l as dialyzing liquid for 2-4 h. This solution should be purified through "Artificial kidney" apparatus, coal sorbent and anion-exchange resin. Perfusion rate of albumin-containing solution in the course of its purification corresponds to 20-30 ml/min. Detoxication cycle with the help of albumin followed by its deligandization should be repeated many times. The innovation provides optimal mode of perfusion and, thus, high rate of toxins elimination through patient's peritoneum and excludes the necessity in applying anticoagulants and expensive "MARS" system.
Prolonged interferon solution / 2270692
Claimed prolonged solution contains human recombinant alpha-2 interferon, citric acid, boric acid, sodium tetraborate, unithiol, human serum albumin, sodium chloride, sodium carboxymethylcellulose and purified water. Preparation of present invention has wide spectrum of therapeutic application.
Method for treatment and prophylaxis of dyspepsia toxic form in newborn calves / 2271198
Calves are intaken with milk with preliminary addition of the following components, g/l: sodium hydrocarbonate, 5-10; serum albumin, 50-60; sodium acetate, 20-50, and sodium chloride 8-9 for 6-8 days. Method is effective in prophylaxis and treatment of newborn calves in acute and toxic forms of dyspepsia.
 Method for production of veterinary albumin / 2286350
Claimed method includes four-step deposition of blood plasma protein fractions with alcohol solution, wherein before deposition said albumin binding ability (ABA) is determined by fluorescence method using cation probes. ABA value is defined as ABA = EAC/TAC.100 %, wherein EAC is effective albumin concentration, and TAC is total albumin concentration. After albumin fraction providing blood plasma ABA is determined again by fluorescence method, obtained albumin fraction is purified on carbohydrate sorbents, blood plasma ABA is determined again by fluorescence method, purified albumin is stabilized with sodium chloride up to final concentration of 10-20 %, defecated by filtration, pasteurized and finally stabilized.
Chemotherapy method for treating malignant tumors of the central nervous system / 2290202
Method involves mixing patient liquor with 3 ml of 10% albumin solution, with chemopreparation and incubating. Then, the mixture is introduced via catheter into subarchnoid space. Repeated introduction is carried out 7 days later.
 Albumin solution and method for production thereof / 2305556
Claimed method includes a) treatment of the first aqueous albumin solution to virus inactivate using SD (solvent/detergent) method by contacting with SD reagents at temperature lower 45°C; b) SD reagent removing by oil extraction followed by chromatography of hydrophobic interaction wherein hydrophobic matrix, in particular matrix wherein hydrophobic groups may optionally bond thereto, is used in said chromatography with the proviso that abovementioned groups represent aliphatic C24+-groups, to produce the second albumin solution; optionally c) addition to the second solution one or more stabilizers selected from group containing sugars, amino acids, and sugar alcohol wherein as said stabilizer indole stabilizer and C6-C10-fatty acid are not used; and d) finished packing of optionally stabilizer-containing second solution followed by sterilizing filtration and optionally container filling therewith. Albumin solution of present invention has binding ability by 10 % higher in contract with albumin treated by pasteurization.
Method for treating ablation retinae cases / 2318478
Method involves intravitreally smoothing out central retina zone by means of perfluororganic substance. Circular retinotomy is carried out after perfluororganic substance smoothing-out. The, conjugate of chlorine e6 bound in covalent way with albumin in 1:2.5 proportion. Later on, the rest of perfluororganic substance is introduced. Retina is circularly intravitreally irradiated in accumulated conjugate projection zone with continuous laser beam of 400 mW power field-by-field during 2 min. Wavelength corresponds to chlorine e6 light absorption maximum. Irradiation being finished, the perfluororganic substance is substituted with silicon oil.
 Method for producing polarized lymphocytes for modeling th2-induced edema / 2318525
Method involves carrying out conventional mice hyperimmunization of BAlb/c for producing polarized lymphocytes with three-fold subcutaneous ovalbumin introduction at a dose of 100 mcg/mouse and aluminum hydroxide adjuvant introduction at a dose of 5 mg/mouse making 14 days long pause between injections. Spleens are taken and lymphocytes are separated 7 days later after the last injection.
 Method for preparing aqueous-alcoholic solution and alcoholic, pharmaceutical and cosmetic products prepared with its using / 2243992
Method involves the separate protonation of purified drinking water by addition to its 0.05-0.2 wt.-% of proton donors that are stronger than water and ethyl alcohol, by addition to its 0.1-0.5 wt.-% of proton donors that are stronger than ethyl alcohol, additional protonation of water and alcohol. For this purpose water and ethyl alcohol are fed by separate flows into two cylindrical glass or porcelain vessels wherein stirring is carried out for 1-5 min using, respectively, glass or porcelain mixers rotating at the rate 1000-3000 rev/min followed by separate filtration of water and alcohol flows and their mixing. Alcoholic product comprises the solution prepared by the proposed method as an aqueous-alcoholic solution. Pharmaceutical product contains effective dose of curative substance and pharmaceutically acceptable medium wherein product comprises an aqueous-alcoholic solution prepared by indicated method. Cosmetic product contains effective dose of active substance and cosmetically acceptable medium wherein it comprises an aqueous-alcoholic solution. Invention provides enhancing quality of the end product. Invention can be used for manufacturing alcoholic production and in pharmacology and cosmetology.
|
FIELD: cosmetology. SUBSTANCE: human serum albumin (HAS) should be obtained out of transgenic animals, not out of men, to be mixed with corresponding carrier and/or adjuvant. HAS should be obtained out of cattle, sheep, swine, horse, rodents or goat. HAS should be obtained either out of milk or blood of transgenic animals, not out of men. HAS should be obtained out of an egg of transgenic poultry. Cosmetic composition should be obtained due to similar technique. Cosmetic composition is either lotion, cream, gel or oil to be applied in case of cosmetic treating wrinkles, scars and burn wounds. The present innovation enables to cheapen the product at keeping its high activity. EFFECT: higher efficiency of application. 19 cl
The present invention relates to methods of producing cosmetic compositions comprising human serum albumin (HSA), where HSA obtained from transgenic animals. The invention also relates to cosmetic compositions that can be obtained by this method. Albumin is the most abundant soluble protein in vertebrates and at the same time represents the protein with the highest concentration in plasma. People HSA is produced in the liver in the form of a globular, replicationmanager protein with a molecular mass of 65 kDa. This protein is involved in a large number of essential functions that include regulation of blood pressure and osmotic pressure in the circulation system, as well as the transportation of fatty acids, amino acids, bile pigments, and many molecules of serum. To maintain normal osmotic pressure in a patient suffering from fluid loss, such as in the case of surgery, shock, burn, or swelling, the HSA is administered as a substitute for plasma. For this purpose HSA currently produced by fractionation of blood collected from blood donors. However, this method of obtaining inevitably involves the risk of contamination by infectious agents such as hepatitis, human immunodeficiency virus, etc. So the removal of HSA is C human blood includes pasteurization of the product and is very expensive. It is well known that HSA is a major component of human skin. Cosmetic use HSA isolated from human blood, it was planned, but was never implemented because such application would be contrary to the ethical concepts. Due to costly allocation method HSA from the blood of the cosmetic use of HSA, thus obtained, Smoking, in addition, because of the cost of a given protein. Because an increasing number of blood products, such as coagulation factors produced by recombinant expression of the genes encoding these factors, the market dynamics will continue to increase the relative cost of purification of HSA from the blood. To ensure adequate supplies of HSA for pharmaceutical applications in this area have developed various alternative ways to get the HSA, in most of which use recombinant expression of the genes encoding this protein. Cloning of cDNA encoding the HSA, in the expression vector, transformation of bacterial or yeast host cells with this vector, culturing the transformed hosts and the allocation thus obtained HSA, as described, for example, in EP 074646, EP 091527, EP 366400 and EP 612761. One of the problems associated with the allocation S from recombinant host cells is based on the fact that the mod is cnie microbial components, such as bacterial or yeast proteins, or lipids, are highly antigenic for humans and, thus, the HSA must be sufficiently purified. The fact that the HSA as a squirrel-media inherent binding activity against a variety of microbial products and components, tissue culture, additionally complicates the scheme schistki and its effectiveness. As an alternative method of obtaining recombinant HSA was suggested obtaining transgenic animals expressing HSA, preferably with expressing vectors capable of expression in the milk of transgenic animals. In WO 91/08216, for example, described receiving expressing vector containing full-length genomic gene HSA under the control of the 5'- and 3'-regulatory sequences derived from the gene αS1-casein cattle. This vector is used for transformation in vitro Mature and fertilizing oocytes by microinjection. Oocytes consistently cultivated in vitro, transferred into cows and give the opportunity to develop in transgenic animals. HSA secreted in the milk data of transgenic animals. In addition, HSA cDNA expressed under the control of promoter β-lactoglobulin in transgenic animals, which also resulted in the secretion of HSA in the milk of animals (WO 93/93164). How dedicated is I recombinant HSA from the milk of transgenic animals are also described in this field. For example, in WO 96/02573 described that HSA can be selected by clearing from the milk of transgenic animals according to the way in which with milk skim the cream off, then remove casein by precipitation of acid and subjected to chromatography using a column with blue separate Cibacron that is suitable for specific binding of HSA, and thus ensuring the separation of HSA and the corresponding bovine protein, bovine serum albumin (hereinafter designated as BSA). BSA is widely used as active compounds in cosmetic preparations, such as creams and lotions, to achieve conditioning of the skin (see CTFA international dictionary of cosmetic ingredients). Kligman and Christopher (J.Soc. Cosmetics Chemists, 16 (1965), R-562) in this plan indicate that the purified BSA solution quickly smoothes fine wrinkles on aging skin. In a clinical study it was shown that this effect is mainly mechanical and is achieved by the tension of the skin when drying protein (Kligman, A.M. and Papa, S.M., Journ. Soc. Cosm. Chem., Vol. 16 (1965), R). Benhaim and Brun (Parfumerie und Kosmetik, Vol. 770 (1996), p.176-180) even conclude that the tension of the skin no active ingredient still couldn't achieve efficiency, equal to the efficiency of BSA, which was also designated as a “product comparison” in cosmetics. BSA used still in cosmetic preparations, ilocalis cow's blood in slaughterhouses. In addition to its beneficial activity of BSA could be used in cosmetic preparations for several reasons. First of all, people tend to come into contact with products derived from cows, ie, proteins, carbohydrates, lipids, fatty acids etc; these products, thus, in General, have low antigenicity against humans. In addition, local application of protein causes less allergic than other application methods, such as injection. Therefore cosmetic use BSA does not require highly purified protein. Thus, the BSA is available at a price that allows its incorporation into a cosmetic product. However, recent reports of infectious diseases spongiform encephalopathy (TSE/BSE, BSE in cattle) and the fact that the transmission of these diseases to humans through cosmetic product can not be completely avoided, has led to a situation where products from cattle must be removed from the cosmetic products. The use of alternative sources of albumin described in this area previously. For example, U.S. patent 4863733 relates to a method of cosmetic treatment of the people, on which a person receives blood secrete albumin and re-injected to the patient to achieve conditioning of the skin near chromo is or areas implantation. While this method can be used for autologous donation HSA, cases heterologous donation again would be contrary to the ethical principles would include the risk of transmitting infections and would be too expensive. As alternative sources of albumin, in addition, it was assumed eggs and swine ovaries or placenta (U.S. patent 2043657 and U.S. patent 3041245). In EP 180968 and EP 244849 describes cosmetic preparations containing HSA. Stated that HSA can be obtained by recombinant expression in bacterial or yeast cells. However, as emphasized above, the expression in microorganisms inevitably leads to contamination of microbial antigens and antigens of the cell cultures. Therefore, HSA, obtained from the data sources must be cleaned to an extremely high level in order to obtain a composition that can be used by people. Cleaning is so expensive that the corresponding method will not result in a commercial product. The problem underlying the present invention, therefore, consists in obtaining a cosmetic product with reasonable price that includes an active connection that surpasses the characteristics of the BSA. This problem is solved by a method for obtaining a cosmetic composition, including HSA, where (a) HSA obtained from Tran the gene animals not a man, and (b) the HSA is mixed with a suitable carrier and/or adjuvant. The present invention also relates to cosmetic compositions that can be obtained by the above method. In the present invention revealed that HSA obtained from transgenic animals, non-human, may be used to obtain cosmetic compositions. Transgenic animals are usually kept in a closed controlled herds that are compatible with good practice production. Therefore, the collection of serum albumin from transgenic animals that were specific selected and about which it is known that they are not infected with pathogens and kept isolated from other animals, does not include the risk of transmission of infectious diseases such as BSE/TSE. The present invention HSA can be obtained from any transgenic animal, not a person, which expresses the gene HSA. However, HSA preferably get from cattle, sheep, pigs, horses, rodents or goats. For the purposes of this application the term “HSA” is used to refer to the human protein albumin superfamily, originally discovered in human blood, and their natural or synthetically modified variants. A number of polymorphisms and mutants man is ical albumin is known to specialists in this field (.Peters, All about Albumin. Biochemistry, Genetics and Medical Applications, Academic Press Inc., 1996) and are covered by the term “HSA”, as well as fragments of human protein that includes at least 1/3 and preferably 2/3 protein sequence. Other options can be obtained by substitution, insertion or addition of nucleotides to the gene, codereuse HSA and covered by the term “HSA”, as used in this application, up until the nucleotide sequence of HSA has homology equal to at least 75% relative to the natural sequence, where it is preferable homology equal to at least 85%, and most preferred is a homology equal to at least 90%. Methods of transformation of the individual animal cells, non-human, heterologous DNA that encodes a interesting alien protein and a regulatory sequence for expression of this protein in the transgenic animal, and the means of reproduction of transgenic animals is well known to specialists in this field (WO 91/08216; Bondioli et al., Biotechnology, Vol. 16 (1991), 265; Ebert et al., Bio/Technology, Vol. 9 (1991), 835; Hammer et al., Nature, Vol. 315 (1985), 680; Houdebine L.M. (ed), Transgenic Animals - Generation and Use, Harwood Academic Publishers GmbH (1996), Amsterdam; C.A. Pinkert (ed), Transgenic Animal Technology: A Laboratory Handbook. Academic Press, San Diego (1994), CA)). Cells can be transformed nucleic acid according to any one of the many way is, previously known in this field. For example, transgenic animals, non-human, can be obtained according to the method, including (a) introducing a nucleic acid that encodes a HSA, in a suitable recipient cell, non-human, and (b) reproduction of the transgenic animal, not a man of recipient cells. Recipient cell preferably is an embryonic cell, but can also be used in other cell types. Reproduction of transgenic animal, not a man, from embryonic recipient cells may include the migration of cells into an animal of the female sex, not the person, and enabling the development of the embryo. The method of producing a transgenic animal, not a person, may, in addition, to enable the cloning of animals. Methods cloning of animals is well known to specialists in this field (Baguisi et al., Nature Biotech., Vol. 17 (1999), 456-461; Campbell et al., Nature, Vol. 380 (1996), 64-66; Cibelli et al., Science, Vol. 280 (1998), 1256; Kato et al., Science Vol. 282 (1998), 2095-2098; Schnieke et al., Science, Vol. 278 (1997), 2130-2133; Vignon et al., C.R. Acad. Sci. Paris, Sciences de la vie/Life Sciences Vol. 321 (1998), 735-745; Wakayama et al., Nature, Vol. 394 (1998), 369-374; Wells et al., Biol. Reprod. Vol. 57 (1997), 385-393; Wilmut et al., Nature, Vol. 385 (1997), 813) and can easily apply the present invention to provide a large number of transgenic animal is X. In one implementation of the HSA is obtained from the milk or blood of the transgenic animal, not a person, preferably from the milk of lactating cattle. In an alternative implementation of HSA obtained from eggs of transgenic birds. Transgenic bird preferably is a chicken. Methods protein expression in transgenic chickens so that the protein is transported into the eggs of data chickens, known in the art (see, for example, Morrison et al., Immunotechnology, Vol. 4 (1998), R-125). Parts or products of the transgenic animals, including HSA, such as milk or eggs, can be a cosmetic product. Alternative HSA can partially or completely stand out. The present invention thus also relates to a method for obtaining a cosmetic composition, which includes the extraction of HSA transgenic animal. Many methods of protein purification well known to the person skilled in the art and can be used according to the present invention for the production of purified HSA. If, for example, you must select the HSA from the milk of the transgenic animal, not a person, the allocation method can include a purification step, which preferably is carried out by filtering. Alternative or in addition to cleaning the allocation method HSA may, in addition, in locate one or more stages, where HSA praecipitium from a solution comprising HSA. For example, HSA sweeps can be obtained with a high purity of the milk or blood of a single stage precipitation. Suitable means capable of recriticality HSA known in this field and can be determined by the technician using simple experiments. Subsequently HSA can resuspendable in the desired solvent, using well-known methods. Preferably, the solvent has characteristics that make it easy cosmetic use HSA (pH, selection of ions). How the selection HSA may further include phase chromatographic purification, which can be implemented on any of a large number of ways chromatography, known in this area. The use of affinity or ion-exchange chromatography is preferred. The present invention HSA obtained from a transgenic animal, not a person, not necessarily requires a high degree of purification. The HSA drug used for the preparation of cosmetic compositions, therefore, can, for example, to include the residual amount of BSA in the range 0-10% by weight selected from HSA, preferably in the range of 0.05-2.5%, most preferably in the range of 0.5-1.0% by weight selected from HSA. Cosmetic compounds may also include other substances the STV from transgenic animals such as other proteins, lipids, fatty acids, carbohydrates, etc. Because most people tend to come into contact with the products of these animals, the risk of allergic reactions after application of the preparation according to the present invention is low. Cosmetic composition obtained by the method according to the present invention, may include HSA in any amount suitable for cosmetic formulation. Typically, the number of HSA is in the range from 0.1 to 30% by weight of the cosmetic composition, and preferably in the range from 1 to 15% by weight of the cosmetic composition. The concentration of HSA in the range from 3 to 8% by weight of the cosmetic composition is most preferred. A wide variety of carriers and adjuvants for the preparation of cosmetic products known to specialists in this field (for example, here is a link to Jellinek, Kosmetologie, Dr. Alfred Many examples (oil-in-water and/or water in oil creams, lotions, oils, gels, hydrogels, drugs that block the action of sunlight, drugs used after exposure to sunlight, as well as drugs after shave described in W.Umbach, Kosmetik: Entwicklung, Herstellung u. Application kosmet. Mittel, Thieme, 1955. HSA can be included in any of these drugs by methods well known specialist in this field. Due to its soothing and moisturizing activity HSA preferably included in the “remaining on the surface” (leave-on products, such as hydrogels, creams, gels, blocks the action of sunlight, drugs used after exposure to sunlight and after shaving, and pencils for lips. According to the present invention is the inclusion of HSA in the preparations on the basis of emulsions of oil in water or water in oil and in film forming drugs, which is especially preferable. In addition to HSA, a cosmetic product may include one or more additional active compounds, for example, antibacterial or antifungal compounds. In a further implementation, the present invention relates to cosmetic compositions that can be obtained by the methods described above. Space is political composition may be in any form known cosmetic compositions, but preferably is in the form of lotion, cream, gel or oil. Finally, the present invention also relates to the use of these compositions for conditioning of the skin in General and specifically for cosmetic treatment of wrinkles, scars, and burn wounds. 1. The method of obtaining cosmetic compositions comprising human serum albumin (HSA), where (a) HSA obtained from a transgenic animal, not a man; (b) the HSA is mixed with a suitable carrier and/or adjuvant. 2. The method according to claim 1, where HSA is obtained from cattle, sheep, pigs, horses, rodents or goats. 3. The method according to claim 1 or 2, where HSA is obtained from the milk or blood of the transgenic animal, not a person. 4. The method according to one of claims 1 to 3, where HSA is obtained from the milk of the lactating cow. 5. The method according to claim 1 or 2, where HSA is obtained from the eggs of transgenic birds. 6. The method according to any of the preceding paragraphs, where the stage of obtaining the HSA includes a purification step. 7. The method according to claim 6, where it is cleaned by filtering. 8. The method according to one of claims 1 to 7, where stage receiving HSA includes the precipitation of HSA solution containing HSA. 9. The method according to any one of claims 1 to 8, wherein the stage of receiving the HSA, in addition, includes a step chromatographic purification. 10. The method according to claim 9, where the phase chromatography is carried out by affin is Oh or ion-exchange chromatography. 11. The method according to any one of claims 1 to 10, where HSA isolated from transgenic animals, pavlyushina person, includes residual amounts of bovine serum albumin (BSA) in the range of 0-10% by weight selected from HSA. 12. The method according to claim 11, where the residual quantity of BSA is in the range of 0.05-2.5% by weight selected from HSA. 13. The method according to item 12, where the residual quantity of BSA is in the range of 0.5-1.0% by weight selected from HSA. 14. The method according to any one of claims 1 to 13, where HSA is included in the cosmetic composition at a concentration lying in the range of 0.1-30% by weight of the cosmetic compositions. 15. The method according to 14, where HSA is included in the cosmetic composition at a concentration lying in the range 1-15% by weight of the cosmetic compositions. 16. The method according to clause 15, where HSA is included in the cosmetic composition at a concentration lying in the range of 3-8% by weight of the cosmetic compositions. 17. Cosmetic composition obtained by the method according to any one of claims 1 to 16. 18. Cosmetic composition according to 17, which is a lotion, cream, gel or oil. 19. Cosmetic composition according to one of the 17 or 18 for use in the cosmetic treatment of wrinkles, scars, and burn wounds.
|